As compared to the presence of the variant allele among controls (17.3%), the increased frequency of the KRAS variant was confirmed in breast cancer cases from BRCA1 families (23.5%), but not among breast cancer cases from BRCA2 (13.5%) or non-BRCA1/2 families (15.8%) [10]. This evidence concerns the gene BRCA1 and breast carcinoma.